Gyre Therapeutics (GYRE) Cash & Equivalents (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Cash & Equivalents data on file, last reported at $37.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $37.5 million, up 917.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.5 million (up 917.36% YoY), and the FY2025 annual result was $24.9 million, up 110.81% from the prior year.
• Cash & Equivalents improved to $37.5 million in Q1 2026 per GYRE's latest filing, from $24.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $75.4 million in Q2 2022 and troughed at $2.2 million in Q3 2023.
• A 5-year average of $23.9 million and a median of $23.1 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents plunged 90.48% in 2023, then soared 917.36% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $25.2 million in 2022, then soared by 33.1% to $33.5 million in 2023, then tumbled by 64.79% to $11.8 million in 2024, then surged by 110.81% to $24.9 million in 2025, then surged by 50.75% to $37.5 million in 2026.
• Business Quant data shows GYRE's Cash & Equivalents at $37.5 million in Q1 2026, $24.9 million in Q4 2025, and $40.4 million in Q3 2025.